NASDAQ:BIIBBiogen Stock Price, Forecast & News

Biogen's stock was trading at $294.25 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, BIIB stock has increased by 3.9% and is now trading at $305.71.
View which stocks have been most impacted by Coronavirus.

31 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last year. There are currently 4 sell ratings, 16 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Biogen.

Biogen is scheduled to release its next quarterly earnings announcement on Tuesday, October 27th 2020.
View our earnings forecast for Biogen.

Biogen Inc (NASDAQ:BIIB) posted its quarterly earnings results on Wednesday, July, 22nd. The biotechnology company reported $10.26 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $8.03 by $2.23. The biotechnology company had revenue of $3.68 billion for the quarter, compared to analyst estimates of $3.44 billion. Biogen had a net margin of 40.91% and a return on equity of 50.10%. During the same period last year, the business posted $9.15 EPS.
View Biogen's earnings history.

Biogen announced that its board has approved a share buyback program on Monday, December 23rd 2019, which allows the company to repurchase $5,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to buy shares of its stock through open market purchases. Stock repurchase programs are typically a sign that the company's board of directors believes its stock is undervalued.

Biogen issued an update on its FY20 earnings guidance on Wednesday, July, 22nd. The company provided earnings per share (EPS) guidance of $34.00-36.00 for the period, compared to the Thomson Reuters consensus EPS estimate of $31.98. The company issued revenue guidance of $13.8-14.2 billion, compared to the consensus revenue estimate of $13.90 billion.

31 Wall Street analysts have issued 1 year price targets for Biogen's shares. Their forecasts range from $228.00 to $410.00. On average, they expect Biogen's share price to reach $312.79 in the next year. This suggests a possible upside of 2.3% from the stock's current price.
View analysts' price targets for Biogen.

News stories about BIIB stock have trended very positive this week, InfoTrie reports. The research group identifies positive and negative press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Biogen earned a news sentiment score of 4.0 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term.
View the latest news about Biogen.

Biogen saw a decrease in short interest in July. As of July 31st, there was short interest totaling 2,780,000 shares, a decrease of 14.7% from the July 15th total of 3,260,000 shares. Based on an average daily volume of 1,610,000 shares, the short-interest ratio is currently 1.7 days. Currently, 1.8% of the company's stock are short sold.
View Biogen's Current Options Chain.

Some companies that are related to Biogen include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU), Novavax (NVAX) and Repligen (RGEN).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Biogen investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Amgen (AMGN), Walt Disney (DIS), Celgene (CELG), Micron Technology (MU) and Intel (INTC).

Biogen trades on the NASDAQ under the ticker symbol "BIIB."

Biogen's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include LSV Asset Management (0.64%), Sumitomo Mitsui Trust Holdings Inc. (0.48%), Swiss National Bank (0.43%), Robeco Institutional Asset Management B.V. (0.25%), First Trust Advisors LP (0.24%) and New York State Common Retirement Fund (0.23%). Company insiders that own Biogen stock include Alexander J Denner, Brian S Posner, Michael D Ehlers, Michel Vounatsos, Robert W Pangia and Stephen A Sherwin.
View institutional ownership trends for Biogen.

BIIB stock was sold by a variety of institutional investors in the last quarter, including Banco Santander S.A., Russell Investments Group Ltd., First Trust Advisors LP, LSV Asset Management, Ziegler Capital Management LLC, Candriam Luxembourg S.C.A., New York State Common Retirement Fund, and Pzena Investment Management LLC. Company insiders that have sold Biogen company stock in the last year include Brian S Posner, and Stephen A Sherwin.
View insider buying and selling activity for Biogen.

BIIB stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., PGGM Investments, Robeco Institutional Asset Management B.V., SG Americas Securities LLC, MERIAN GLOBAL INVESTORS UK Ltd, State of Michigan Retirement System, QCI Asset Management Inc. NY, and Railway Pension Investments Ltd. Company insiders that have bought Biogen stock in the last two years include Alexander J Denner, and Michel Vounatsos.
View insider buying and selling activity for Biogen.

Shares of BIIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of BIIB stock can currently be purchased for approximately $305.71.

Biogen has a market capitalization of $48.40 billion and generates $14.38 billion in revenue each year. The biotechnology company earns $5.89 billion in net income (profit) each year or $33.57 on an earnings per share basis. Biogen employs 7,400 workers across the globe.

The official website for Biogen is www.biogen.com.

Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-679-2000 or via email at [email protected]